

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

INSIDE INFORMATION – 2021 PRELIMINARY RESULTS

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) as well as the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Please also refer to the overseas regulatory announcement of the Company dated 25 February 2022.

The principal consolidated financial data of the Company for the year ended 31 December 2021 (the “**Reporting Period**”) set out in this announcement is prepared in accordance with the China Accounting Standards for Business Enterprises, and is only preliminary estimated data, and has not been audited. This preliminary results is prepared pursuant to the relevant regulations of the Shanghai Stock Exchange and the People's Republic of China. The audited financial data of the Company for the Reporting Period will be disclosed in the 2021 annual report of the Company (prepared in accordance with PRC GAAP) to be published on the Shanghai Stock Exchange website (<http://www.sse.com.cn>), and the 2021 annual results announcement and the 2021 annual report of the Company (prepared in accordance with International Financial Reporting Standards) to be published on the websites of the Company (www.junshipharma.com) and The Stock Exchange of Hong Kong Limited (<http://www.hkexnews.hk>). Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.

I. MAJOR FINANCIAL DATA AND INDICATORS FOR 2021

Unit: RMB'0,000

Item	The Reporting Period	Corresponding period of last year	Change (%)
Total operating income	401,449.73	159,489.66	151.71
Operating loss	(57,538.82)	(165,608.20)	N/A
Total loss	(61,211.41)	(167,242.93)	N/A
Net loss attributable to owners of the parent company	(73,887.58)	(166,860.68)	N/A
Net loss attributable to owners of the parent company after deducting non-recurring gains and losses	(92,230.95)	(170,882.50)	N/A
Basic loss per share (RMB)	(0.83)	(2.03)	N/A
Weighted average returns on net assets	(11.15%)	(41.58%)	N/A
	At the end of the Reporting Period	At the beginning of the Reporting Period	Change (%)
Total assets	1,104,495.04	799,740.95	38.11
Equity attributable to owners of the parent company	792,712.94	582,780.85	36.02
Share capital (share)	91,075.67	87,249.60	4.39
Net assets per share attributable to owners of the parent company (RMB)	8.70	6.68	30.24

Notes: 1. The data as at the beginning of the Reporting Period is the same as the data disclosed statutorily as at the end of last year.

2. The financial data and indicators above are extracted from the data of the consolidated financial statements and are unaudited. The final results are subject to the 2021 annual report of the Company.

II. EXPLANATION ON THE OPERATING RESULTS AND FINANCIAL POSITION

(I) Operating conditions, financial position and major factors affecting the operating results during the Reporting Period

It is estimated that the Company's operating revenue would increase significantly during the Reporting Period, which the Company considers to be mainly attributable to the substantial increase in licensing income, the newly recorded royalty income, and sales revenue from commercialisation of the domestic market of Toripalimab Injection (trade name: 拓益® (TUOYI®)). In particular, with respect to licensing income and royalty income:

1. pursuant to the research collaboration and license agreement entered into between the Company and Eli Lilly and Company (“Lilly”), by virtue of the rapid progress of the cooperation, all milestone events agreed upon in the overseas licensing of etesevimab (JS016/LY-CoV016) to Lilly have been completed. In addition, the Company entered into an exclusive license and commercialisation agreement with Coherus BioSciences, Inc., pursuant to which both parties agreed to carry out in-depth cooperation in the field of tumor immunotherapy in the United States and Canada. Based on the above two cooperation projects, the Company's licensing income is estimated to increase significantly during the Reporting Period.
2. in view of the overseas development of the COVID-19 pandemic, as of the end of the Reporting Period, etesevimab and bamlanivimab (LY-CoV555) administered together has obtained emergency use authorisations in over 15 countries and regions. Along with the commercialisation of such therapy, the Company would record new royalty income during the Reporting Period.

During the Reporting Period, the Company continued to increase R&D investment, continuously diversified and expanded its product pipeline through independent R&D, co-development/license-in and other means, continuously explored the combination therapy of drugs, accelerated the development of existing clinical projects and reserved R&D projects, as well as accelerated the development of a number of product pipelines with first-in-class or differentiated development value. During the Reporting Period, more than ten self-developed or cooperative development projects of the Company have been approved for clinical trials; three new indications for toripalimab have been approved for marketing by the National Medical Products Administration (the “NMPA”); two supplemental New Drug Applications have been accepted by the NMPA. As at the date of this announcement, the Company's R&D pipeline has expanded to over 45 pipeline assets, covering five major therapeutic areas. Amongst them, there are two assets (toripalimab and etesevimab) at the stage of commercialisation and one asset (adalimumab) at the stage of New Drug Application. In addition to the above assets, there are over 20 assets at the stage of clinical trials.

(II) Main reasons for the changes in the major indicators

1. During the Reporting Period, the operating income of the Company increased by 151.71% as compared with the same period of last year, which was mainly due to the substantial increase in licensing income, the newly recorded royalty income, and sales revenue from commercialisation of the domestic market of Toripalimab Injection (trade name: 拓益® (TUOYI®)).

2. During the Reporting Period, the operating loss, total loss, net loss attributable to owners of the parent company, net loss attributable to owners of the parent company after deducting non-recurring gains and losses, basic loss per share and the loss in respect of the weighted average returns on net assets reduced as compared with the loss recorded in the same period of last year, which were mainly due to the substantial increase in licensing income and the newly recorded royalty income.
3. During the Reporting Period, total assets, equity attributable to owners of the parent company, share capital and net assets per share attributable to owners of the parent company increased by 38.11%, 36.02%, 4.39% and 30.24% as compared with the same period of last year respectively, which were mainly due to the receipt of raised funds from the placing of new H shares by the Company during the Reporting Period.

III. RISK WARNING

The Company is not aware of any material uncertainties that will affect the accuracy of the content of this preliminary results announcement.

The major financial data for 2021 contained in this announcement is only preliminary estimated data, and has not been audited by the Company's auditors. Please refer to the 2021 annual report of the Company (prepared in accordance with PRC GAAP) to be published on the Shanghai Stock Exchange website (<http://www.sse.com.cn>), and the 2021 annual results announcement and the 2021 annual report of the Company (prepared in accordance with International Financial Reporting Standards) to be published on the websites of the Company (www.junshipharma.com) and The Stock Exchange of Hong Kong Limited (<http://www.hkexnews.hk>) for specific audited data. Investors and shareholders of the Company are reminded of the investment risks.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 25 February 2022

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng and Mr. Li Cong as executive directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive directors.

* For identification purpose only